Brain chemical booster may unlock secrets of learning
NCT ID NCT07239791
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how a low-dose drug that increases noradrenaline (a brain chemical) affects learning in 160 healthy adults. Participants will take either the drug or a placebo and perform tasks that measure how they learn from new information. The goal is to better understand the brain's learning processes, which could help with conditions like ADHD or depression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 160 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2025
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 39 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Right-handed, assessed by the Edinburgh scale; * Written signed informed consent; * Subject covered by a social security regimen. Exclusion Criteria: * Pregnant, parturient or breastfeeding woman; * First-degree family history of axis I disorder (DSM-IV-TR), excepted unipolar mood and anxiety disorders with OCD; * Personal history of axis I disorder (DSM-IV-TR) in the 6 months preceding the study entry; * Dependence on a psychoactive substance in the 12 months preceding the study entry, excluding nicotine, any behavioural disorder incompatible with a 2-hour electroencephalographic recording; * Neuro/psychotropic treatment ongoing or stopped less than 1 month ago; * Personal history of neurological pathology (e.g.: congenital malformation, benign or malignant tumour, degenerative disease of the central nervous system (CNS), epilepsy, inflammatory or infectious disease of the CNS, etc.); * Personal history of chronic disease of infectious, neoplastic, vascular, dysimmune or inflammatory, metabolic or endocrine, degenerative or genetic aetiology. In particular, angle-closure glaucoma, pheochromocytoma, known high blood pressure or measured blood pressure greater than 140/90 mm Hg at baseline, congenital heart disease, known ischemic heart disease, known heart failure, supraventricular or ventricular heart rhythm disorder, nephropathy, known liver disease and any pathology likely to be aggravated by an increase in blood pressure; * Any medical treatment in the month preceding the study entry, apart from effective contraceptive treatment; * Subject deprived of liberty by a judicial or administrative decision; * Person subject to a legal protection measure or unable to express consent; * Known intolerance to atomoxetine; * Need to wear glasses and/or lenses to obtain normal vision; * Subject in an exclusion period or enrolled in an interventional study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for No disease or condition is being studied are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Institut de Neuromodulation
RECRUITINGParis, 75014, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Power nap study: 25 minutes to sharper focus and less stress?
- Jump higher, run faster: plyometric training shows promise for young footballers
- Robotic surgery showdown: hand vs foot clutch in training
- CBG study: can this cannabis compound boost mood or memory?
- New online program aims to ease stress for korean american dementia caregivers
- Lab study aims to sharpen eye biopsy techniques